Rybak SM - Search Results

1

Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent.

Altomare DA, Rybak SM, Pei J, Maizel JV, Cheung M, Testa JR, Shogen K. Altomare DA, et al. Among authors: rybak sm. BMC Cancer. 2010 Feb 5;10:34. doi: 10.1186/1471-2407-10-34. BMC Cancer. 2010. PMID: 20137089 Free PMC article.

2

A gender-specific mRNA encoding a cytotoxic ribonuclease contains a 3' UTR of unusual length and structure.

Chen S, Le SY, Newton DL, Maizel JV Jr, Rybak SM. Chen S, et al. Among authors: rybak sm. Nucleic Acids Res. 2000 Jun 15;28(12):2375-82. doi: 10.1093/nar/28.12.2375. Nucleic Acids Res. 2000. PMID: 10871370 Free PMC article.

3

Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease.

Rybak SM, Pearson JW, Fogler WE, Volker K, Spence SE, Newton DL, Mikulski SM, Ardelt W, Riggs CW, Kung HF, Longo DL. Rybak SM, et al. J Natl Cancer Inst. 1996 Jun 5;88(11):747-53. doi: 10.1093/jnci/88.11.747. J Natl Cancer Inst. 1996. PMID: 8637029

4

Toxicity of an antitumor ribonuclease to Purkinje neurons.

Newton DL, Walbridge S, Mikulski SM, Ardelt W, Shogen K, Ackerman SJ, Rybak SM, Youle RJ. Newton DL, et al. Among authors: rybak sm. J Neurosci. 1994 Feb;14(2):538-44. doi: 10.1523/JNEUROSCI.14-02-00538.1994. J Neurosci. 1994. PMID: 8301353 Free PMC article.

5

Molecular determinants of apoptosis induced by the cytotoxic ribonuclease onconase: evidence for cytotoxic mechanisms different from inhibition of protein synthesis.

Iordanov MS, Ryabinina OP, Wong J, Dinh TH, Newton DL, Rybak SM, Magun BE. Iordanov MS, et al. Among authors: rybak sm. Cancer Res. 2000 Apr 1;60(7):1983-94. Cancer Res. 2000. PMID: 10766189

6

"Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies.

Rybak SM, Sanovich E, Hollingshead MG, Borgel SD, Newton DL, Melillo G, Kong D, Kaur G, Sausville EA. Rybak SM, et al. Cancer Res. 2003 Jun 1;63(11):2812-9. Cancer Res. 2003. PMID: 12782586

7

Unique recombinant human ribonuclease and inhibition of Kaposi's sarcoma cell growth.

Newton DL, Rybak SM. Newton DL, et al. Among authors: rybak sm. J Natl Cancer Inst. 1998 Dec 2;90(23):1787-91. doi: 10.1093/jnci/90.23.1787. J Natl Cancer Inst. 1998. PMID: 9839518

8

Anti-CD22 Onconase: preparation and characterization.

Newton DL, Stockwin LH, Rybak SM. Newton DL, et al. Among authors: rybak sm. Methods Mol Biol. 2009;525:425-43, xiv. doi: 10.1007/978-1-59745-554-1_22. Methods Mol Biol. 2009. PMID: 19252847

9

Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.

Newton DL, Hansen HJ, Liu H, Ruby D, Iordanov MS, Magun BE, Goldenberg DM, Rybak SM. Newton DL, et al. Among authors: rybak sm. Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):79-86. doi: 10.1016/s1040-8428(01)00116-0. Crit Rev Oncol Hematol. 2001. PMID: 11418304 Review.

10

Antibody-onconase conjugates: cytotoxicity and intracellular routing.

Rybak SM. Rybak SM. Curr Pharm Biotechnol. 2008 Jun;9(3):226-30. doi: 10.2174/138920108784567272. Curr Pharm Biotechnol. 2008. PMID: 18673288 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

76 results

Search Page